159
Participants
Start Date
August 5, 2008
Primary Completion Date
November 27, 2008
Study Completion Date
November 27, 2008
PF-04136309
125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
Placebo
Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
Commonwealth Orthopaedics and Rehabilitation PC, Arlington
IntegraTrials, LLC, Arlington
United Hospital Center Clinical Trials Office, Clarksburg
University Clinical Research-DeLand, LLC, DeLand
Arthritis & Rheumatic Care Center, South Miami
Miami Research Associates, South Miami
Commonwealth Biomedical Research, LLC, Madisonville
New Horizons Clinical Research, Cincinnati
Covenant Health and Wellness Center, Chesterfield
Metro Imaging West County, Creve Coeur
Metro Imaging St. Peters, City of Saint Peters
Diagnostic Imaging Centers, Overland Park
Vince and Associates Clinical Research, Overland Park
Diagnostics Research Group, San Antonio
South Texas Radiology Group, San Antonio
Analgesic Development Limited, New York
Omega Medical Research, Warwick
Statcare, Warwick
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University College of Medicine, Seoul
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Pfizer
INDUSTRY